Macaya Douoguih
About
Macaya Douoguih is a scholar working on Infectious Diseases, Epidemiology and Immunology.
According to data from OpenAlex, Macaya Douoguih has authored 42 papers receiving a total of 707 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Infectious Diseases, 20 papers in Epidemiology and 9 papers in Immunology. Recurrent topics in Macaya Douoguih's work include Viral Infections and Outbreaks Research (18 papers), Hepatitis B Virus Studies (11 papers) and SARS-CoV-2 and COVID-19 Research (9 papers). Macaya Douoguih is often cited by papers focused on Viral Infections and Outbreaks Research (18 papers), Hepatitis B Virus Studies (11 papers) and SARS-CoV-2 and COVID-19 Research (9 papers). Macaya Douoguih collaborates with scholars based in Netherlands, Belgium and United States. Macaya Douoguih's co-authors include Kerstin Lühn, Viki Bockstal, Georgi Shukarev, Benoît Callendret, Cynthia Robinson, Jerald Sadoff, Dickson Anumendem, Stephan Bart, Maria Grazia Pau and Deborah Watson‐Jones and has published in prestigious journals such as New England Journal of Medicine, The Journal of Immunology and PLoS ONE.
In The Last Decade
Macaya Douoguih
40 papers receiving 690 citations
Hit Papers
Peers
Macaya Douoguih
Freja Kirsebom United Kingdom
Jayanthi Wolf United States
Praveen Dhankhar United States
Benoît Callendret Netherlands
Simon P. Jochems Netherlands
Pedro M. Folegatti United Kingdom
Lilian W. Waiboci Kenya
Anna M. Acosta United States
Corwin A. Robertson United States
Monika Redlberger‐Fritz Austria
Citations per year, relative to Macaya Douoguih Macaya Douoguih (= 1×)
peers
Freja Kirsebom
Countries citing papers authored by Macaya Douoguih
Since
Specialization
Citations
This map shows the geographic impact of Macaya Douoguih's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Macaya Douoguih with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Macaya Douoguih more than expected).
Fields of papers citing papers by Macaya Douoguih
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Macaya Douoguih. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Macaya Douoguih. The network helps show where Macaya Douoguih may publish in the future.
Co-authorship network of co-authors of Macaya Douoguih
This figure shows the co-authorship network connecting the top 25 collaborators of Macaya Douoguih. A scholar is included among the top collaborators of Macaya Douoguih based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Macaya Douoguih. Macaya Douoguih is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Vaissière, Nathalie, Carla Truyers, Erik Buntinx, et al.. (2025). Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trial. EClinicalMedicine. 79. 103016–103016.
2.
Rampelbergh, Rian Van, Sue Pavord, Karin Hardt, et al.. (2025). Comparison of vaccine-induced immune thrombocytopenia and thrombosis cases following two adenovirus-vectored COVID-19 vaccines. Communications Medicine. 5(1). 168–168.
3.
Pollard, Andrew J., Catherine Schmidt‐Mutter, Fabrice Lainé, et al.. (2024). Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study. Vaccines. 12(2). 210–210.
4.
Gars, Mathieu Le, Jerald Sadoff, Vicky Cárdenas, et al.. (2024). Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial. Vaccine. 42(19). 3938–3952.
5.
Cárdenas, Vicky, Mathieu Le Gars, Carla Truyers, et al.. (2024). Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study. Vaccine. 42(16). 3536–3546.
6.
Prague, Mélanie, Chelsea McLean, Viki Bockstal, et al.. (2023). Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola. npj Vaccines. 8(1). 174–174.
7.
Watson‐Jones, Deborah, Hugo Kavunga‐Membo, Rebecca F. Grais, et al.. (2022). Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo. BMJ Open. 12(3). e055596–e055596.
8.
Bockstal, Viki, Georgi Shukarev, Chelsea McLean, et al.. (2022). First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study. PLoS ONE. 17(10). e0274906–e0274906.
9.
Sadoff, Jerald, Mathieu Le Gars, Boerries Brandenburg, et al.. (2022). Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials. Vaccine. 40(32). 4403–4411.
10.
Bockstal, Viki, Maarten Leyssen, Dirk Heerwegh, et al.. (2022). Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola. npj Vaccines. 7(1). 156–156.
11.
Ong‐Lim, Anna Lisa, Georgi Shukarev, Gert C. Scheper, et al.. (2022). Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age. Human Vaccines & Immunotherapeutics. 18(5). 2044255–2044255.
12.
Bockstal, Viki, Auguste Gaddah, Neil Goldstein, et al.. (2021). Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen. npj Vaccines. 6(1). 157–157.
13.
Custers, Jerome, Maarten Leyssen, Marc Gurwith, et al.. (2020). Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment. Vaccine. 39(22). 3081–3101.
14.
Mutua, Gaudensia, Omu Anzala, Kerstin Lühn, et al.. (2019). Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya. The Journal of Infectious Diseases. 220(1). 57–67.
15.
Nyendak, Melissa, Gwendolyn Swarbrick, Meghan Cansler, et al.. (2016). Adenovirally-Induced Polyfunctional T Cells Do Not Necessarily Recognize the Infected Target: Lessons from a Phase I Trial of the AERAS-402 Vaccine. Scientific Reports. 6(1). 36355–36355.
16.
Walsh, Douglas S., Mark E. Polhemus, Lucas Otieno, et al.. (2016). Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON®-TB Gold (+) Kenyan adults without evidence of tuberculosis. Vaccine. 34(21). 2430–2436.
17.
Sheehan, Sharon R., Stephanie A. Harris, Iman Satti, et al.. (2015). A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults. PLoS ONE. 10(11). e0141687–e0141687.
18.
Hokey, David A., Patricia A. Darrah, Diane L. Bolton, et al.. (2014). A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine. Human Vaccines & Immunotherapeutics. 10(8). 2199–2210.
19.
Morris, Carrie A., Marie Onyamboko, Edmund V. Capparelli, et al.. (2011). Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria. Malaria Journal. 10(1). 114–114.
20.
Douoguih, Macaya. (2008). Accessing Maternal Health Services in Eastern Burma. PLoS Medicine. 5(12). e250–e250.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Freja Kirsebom Breakdown of academic impact, for papers by Jayanthi Wolf Breakdown of academic impact, for papers by Praveen Dhankhar Breakdown of academic impact, for papers by Benoît Callendret Breakdown of academic impact, for papers by Simon P. Jochems Breakdown of academic impact, for papers by Pedro M. Folegatti Breakdown of academic impact, for papers by Lilian W. Waiboci Breakdown of academic impact, for papers by Anna M. Acosta Breakdown of academic impact, for papers by Corwin A. Robertson Breakdown of academic impact, for papers by Monika Redlberger‐Fritz